Rapamycin
mTOR inhibitor / Clinically useful immunosuppressant. Inhibits the response to interleukin-2 blocking activation of T- and B-cells.1 Rapamycin forms a complex with cytosolic FK-binding protein 12 (FKB12) that binds to mTOR Complex1(mTORC1) inhibiting the mammalian target of rapamycin (mTOR).2 Also binds to mTORC2 leading to decreased glucose tolerance and insensitivity to insulin.3 Induces autophagy.4
Biochemicals & reagents
53123-88-9
Sirolimus; AY-22989; WY-090217; NSC-226080; Rapamune
1) Kay, et al. (1991) Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72 544 / 2) Mita, et al., (2003) The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol. Ther. 2(4 Suppl 1), S169 / 3) Lamming, et al. ( 2012). Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335 1638 / 4) Sarkar et.al. (2009), Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies Cell Death and Differentiation 16, 46
-20°C
TARGET: Kinase; Antibiotic; PPIase -- PATHWAY: mTOR; Autophagy; Cytokine; Cell cycle; Apoptosis inhibitor; Senescence -- RESEARCH AREA: Cell death; Immunology; Wound healing -- DISEASE AREA: Diabetes; Infectious diseaseInflammation; Heart disease; Ageing